FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801596150> ?p ?o ?g. }

• W2801596150 endingPage "1070" @default.
• W2801596150 startingPage "1061" @default.
• W2801596150 abstract "In the phase III METEOR trial, tyrosine kinase inhibitor cabozantinib significantly improved progression-free survival (PFS), objective response rate (ORR), and overall survival compared to everolimus in patients with advanced renal cell carcinoma (RCC) who had received prior VEGFR inhibitor therapy. In METEOR, RCC patients started at a daily 60-mg cabozantinib tablet (Cabometyx™) dose but could reduce to 40- or 20-mg to achieve a tolerated exposure.Exposure-response (ER) models were developed to characterize the relationship between cabozantinib at clinically relevant exposures in RCC patients enrolled in METEOR and efficacy (PFS and tumor response) and safety endpoints.Compared to the average steady-state cabozantinib concentration for a 60-mg dose, exposures at simulated 40- and 20-mg starting doses were predicted to result in higher risk of disease progression or death [hazard ratios (HRs) of 1.10 and 1.39, respectively], lower maximal median reduction in tumor size (- 11.9 vs - 9.1 and - 4.5%, respectively), and lower ORR (19.1 vs 15.6 and 8.7%, respectively). The 60-mg exposure was also associated with higher risk for selected adverse events (AEs) palmar-plantar erythrodysesthesia syndrome (grade ≥ 1), fatigue/asthenia (grade ≥ 3), diarrhea (grade ≥ 3), and hypertension (predicted HRs of 2.21, 2.01, 1.78, and 1.85, respectively) relative to the predicted average steady-state cabozantinib concentration for a 20-mg starting dose.ER modeling predicted that cabozantinib exposures in RCC patients at the 60-mg starting dose would provide greater anti-tumor activity relative to exposures at simulated 40- and 20-mg starting doses that were associated with decreased rates of clinically relevant AEs." @default.
• W2801596150 created "2018-05-17" @default.
• W2801596150 creator A5004947301 @default.
• W2801596150 creator A5008080580 @default.
• W2801596150 creator A5008908941 @default.
• W2801596150 creator A5009229956 @default.
• W2801596150 creator A5045719230 @default.
• W2801596150 creator A5061517379 @default.
• W2801596150 date "2018-04-17" @default.
• W2801596150 modified "2023-10-16" @default.
• W2801596150 title "Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma" @default.
• W2801596150 cites W1852876364 @default.
• W2801596150 cites W2066604995 @default.
• W2801596150 cites W2079075723 @default.
• W2801596150 cites W2087046564 @default.
• W2801596150 cites W2096065464 @default.
• W2801596150 cites W2100945326 @default.
• W2801596150 cites W2109706412 @default.
• W2801596150 cites W2131368580 @default.
• W2801596150 cites W2135139265 @default.
• W2801596150 cites W2157975224 @default.
• W2801596150 cites W2222086386 @default.
• W2801596150 cites W2319048980 @default.
• W2801596150 cites W2415950182 @default.
• W2801596150 cites W2484295046 @default.
• W2801596150 cites W2540957952 @default.
• W2801596150 cites W801104115 @default.
• W2801596150 doi "https://doi.org/10.1007/s00280-018-3579-7" @default.
• W2801596150 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5973957" @default.
• W2801596150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29667066" @default.
• W2801596150 hasPublicationYear "2018" @default.
• W2801596150 type Work @default.
• W2801596150 sameAs 2801596150 @default.
• W2801596150 citedByCount "32" @default.
• W2801596150 countsByYear W28015961502018 @default.
• W2801596150 countsByYear W28015961502019 @default.
• W2801596150 countsByYear W28015961502020 @default.
• W2801596150 countsByYear W28015961502021 @default.
• W2801596150 countsByYear W28015961502022 @default.
• W2801596150 countsByYear W28015961502023 @default.
• W2801596150 crossrefType "journal-article" @default.
• W2801596150 hasAuthorship W2801596150A5004947301 @default.
• W2801596150 hasAuthorship W2801596150A5008080580 @default.
• W2801596150 hasAuthorship W2801596150A5008908941 @default.
• W2801596150 hasAuthorship W2801596150A5009229956 @default.
• W2801596150 hasAuthorship W2801596150A5045719230 @default.
• W2801596150 hasAuthorship W2801596150A5061517379 @default.
• W2801596150 hasBestOaLocation W28015961501 @default.
• W2801596150 hasConcept C121608353 @default.
• W2801596150 hasConcept C126322002 @default.
• W2801596150 hasConcept C126894567 @default.
• W2801596150 hasConcept C143998085 @default.
• W2801596150 hasConcept C197934379 @default.
• W2801596150 hasConcept C207103383 @default.
• W2801596150 hasConcept C2777472916 @default.
• W2801596150 hasConcept C2778820342 @default.
• W2801596150 hasConcept C2779490328 @default.
• W2801596150 hasConcept C2779984678 @default.
• W2801596150 hasConcept C2781064419 @default.
• W2801596150 hasConcept C29730261 @default.
• W2801596150 hasConcept C31760486 @default.
• W2801596150 hasConcept C44249647 @default.
• W2801596150 hasConcept C71924100 @default.
• W2801596150 hasConcept C90924648 @default.
• W2801596150 hasConceptScore W2801596150C121608353 @default.
• W2801596150 hasConceptScore W2801596150C126322002 @default.
• W2801596150 hasConceptScore W2801596150C126894567 @default.
• W2801596150 hasConceptScore W2801596150C143998085 @default.
• W2801596150 hasConceptScore W2801596150C197934379 @default.
• W2801596150 hasConceptScore W2801596150C207103383 @default.
• W2801596150 hasConceptScore W2801596150C2777472916 @default.
• W2801596150 hasConceptScore W2801596150C2778820342 @default.
• W2801596150 hasConceptScore W2801596150C2779490328 @default.
• W2801596150 hasConceptScore W2801596150C2779984678 @default.
• W2801596150 hasConceptScore W2801596150C2781064419 @default.
• W2801596150 hasConceptScore W2801596150C29730261 @default.
• W2801596150 hasConceptScore W2801596150C31760486 @default.
• W2801596150 hasConceptScore W2801596150C44249647 @default.
• W2801596150 hasConceptScore W2801596150C71924100 @default.
• W2801596150 hasConceptScore W2801596150C90924648 @default.
• W2801596150 hasIssue "6" @default.
• W2801596150 hasLocation W28015961501 @default.
• W2801596150 hasLocation W28015961502 @default.
• W2801596150 hasLocation W28015961503 @default.
• W2801596150 hasLocation W28015961504 @default.
• W2801596150 hasOpenAccess W2801596150 @default.
• W2801596150 hasPrimaryLocation W28015961501 @default.
• W2801596150 hasRelatedWork W2588916167 @default.
• W2801596150 hasRelatedWork W2801596150 @default.
• W2801596150 hasRelatedWork W2896683739 @default.
• W2801596150 hasRelatedWork W2971476881 @default.
• W2801596150 hasRelatedWork W2994267388 @default.
• W2801596150 hasRelatedWork W3106854003 @default.
• W2801596150 hasRelatedWork W3134949580 @default.
• W2801596150 hasRelatedWork W3161601890 @default.
• W2801596150 hasRelatedWork W4283525470 @default.
• W2801596150 hasRelatedWork W4285598862 @default.
• W2801596150 hasVolume "81" @default.

• next